82 related articles for article (PubMed ID: 20730927)
1. Immobilization of the irreversible thrombin inhibitor D-Phe-Pro-Arg-chloromethylketone: a concept for hemocompatible surfaces?
Maitz MF; Sperling C; Werner C
J Biomed Mater Res A; 2010 Sep; 94(3):905-12. PubMed ID: 20730927
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of thrombin by arginine-containing peptide chloromethyl ketones and bis chloromethyl ketone-albumin conjugates.
Odake S; Kam CM; Powers JC
J Enzyme Inhib; 1995; 9(1):17-27. PubMed ID: 8568563
[TBL] [Abstract][Full Text] [Related]
3. The refined 1.9-A X-ray crystal structure of D-Phe-Pro-Arg chloromethylketone-inhibited human alpha-thrombin: structure analysis, overall structure, electrostatic properties, detailed active-site geometry, and structure-function relationships.
Bode W; Turk D; Karshikov A
Protein Sci; 1992 Apr; 1(4):426-71. PubMed ID: 1304349
[TBL] [Abstract][Full Text] [Related]
4. Thrombin-inhibiting perfluorocarbon nanoparticles provide a novel strategy for the treatment and magnetic resonance imaging of acute thrombosis.
Myerson J; He L; Lanza G; Tollefsen D; Wickline S
J Thromb Haemost; 2011 Jul; 9(7):1292-300. PubMed ID: 21605330
[TBL] [Abstract][Full Text] [Related]
5. Proton bridging in the interactions of thrombin with small inhibitors.
Kovach IM; Kelley P; Eddy C; Jordan F; Baykal A
Biochemistry; 2009 Aug; 48(30):7296-304. PubMed ID: 19530705
[TBL] [Abstract][Full Text] [Related]
6. The effect of antithrombin III-independent thrombin inhibitors and heparin on fibrin accretion onto fibrin-coated polyethylene.
Rubens FD; Weitz JI; Brash JL; Kinlough-Rathbone RL
Thromb Haemost; 1993 Feb; 69(2):130-4. PubMed ID: 8456425
[TBL] [Abstract][Full Text] [Related]
7. D-Phe-Pro-Arg-chloromethylketone: its potential use in inhibiting the formation of in vitro artifacts in blood collected during tissue-type plasminogen activator thrombolytic therapy.
Mohler MA; Refino CJ; Chen SA; Chen AB; Hotchkiss AJ
Thromb Haemost; 1986 Oct; 56(2):160-4. PubMed ID: 2433785
[TBL] [Abstract][Full Text] [Related]
8. Markers of coagulation and fibrinolysis in blood drawn into citrate with and without D-Phe-Pro-Arg-Chloromethylketone (PPACK).
Rahr HB; Sørensen JV; Danielsen D
Thromb Res; 1994 Mar; 73(5):279-84. PubMed ID: 8016814
[TBL] [Abstract][Full Text] [Related]
9. The isomorphous structures of prethrombin2, hirugen-, and PPACK-thrombin: changes accompanying activation and exosite binding to thrombin.
Vijayalakshmi J; Padmanabhan KP; Mann KG; Tulinsky A
Protein Sci; 1994 Dec; 3(12):2254-71. PubMed ID: 7756983
[TBL] [Abstract][Full Text] [Related]
10. Selective albumin-binding surfaces modified with a thrombin-inhibiting peptide.
Freitas SC; Maia S; Figueiredo AC; Gomes P; Pereira PJ; Barbosa MA; Martins MC
Acta Biomater; 2014 Mar; 10(3):1227-37. PubMed ID: 24316365
[TBL] [Abstract][Full Text] [Related]
11. Antithrombin nanoparticles inhibit stent thrombosis in ex vivo static and flow models.
Palekar RU; Vemuri C; Marsh JN; Arif B; Wickline SA
J Vasc Surg; 2016 Nov; 64(5):1459-1467. PubMed ID: 26482989
[TBL] [Abstract][Full Text] [Related]
12. Allosteric changes in solvent accessibility observed in thrombin upon active site occupation.
Croy CH; Koeppe JR; Bergqvist S; Komives EA
Biochemistry; 2004 May; 43(18):5246-55. PubMed ID: 15122890
[TBL] [Abstract][Full Text] [Related]
13. Controlled preparation of thin fibrin films immobilized at solid surfaces.
Riedel T; Brynda E; Dyr JE; Houska M
J Biomed Mater Res A; 2009 Feb; 88(2):437-47. PubMed ID: 18306296
[TBL] [Abstract][Full Text] [Related]
14. Structure and behavior of human α-thrombin upon ligand recognition: thermodynamic and molecular dynamics studies.
Silva Vde A; Cargnelutti MT; Giesel GM; Palmieri LC; Monteiro RQ; Verli H; Lima LM
PLoS One; 2011; 6(9):e24735. PubMed ID: 21935446
[TBL] [Abstract][Full Text] [Related]
15. Active-site-selective labeling of blood coagulation proteinases with fluorescence probes by the use of thioester peptide chloromethyl ketones. I. Specificity of thrombin labeling.
Bock PE
J Biol Chem; 1992 Jul; 267(21):14963-73. PubMed ID: 1634535
[TBL] [Abstract][Full Text] [Related]
16. The effect of immobilization of thrombin inhibitors onto self-assembled monolayers on the adsorption and activity of thrombin.
Freitas SC; Barbosa MA; Martins MC
Biomaterials; 2010 May; 31(14):3772-80. PubMed ID: 20153046
[TBL] [Abstract][Full Text] [Related]
17. Human D-Phe-Pro-Arg-CH2-alpha-thrombin crystallization and diffraction data.
Skrzypczak-Jankun E; Rydel TJ; Tulinsky A; Fenton JW; Mann KG
J Mol Biol; 1989 Apr; 206(4):755-7. PubMed ID: 2738917
[TBL] [Abstract][Full Text] [Related]
18. In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.
Costanzo MJ; Almond HR; Hecker LR; Schott MR; Yabut SC; Zhang HC; Andrade-Gordon P; Corcoran TW; Giardino EC; Kauffman JA; Lewis JM; de Garavilla L; Haertlein BJ; Maryanoff BE
J Med Chem; 2005 Mar; 48(6):1984-2008. PubMed ID: 15771442
[TBL] [Abstract][Full Text] [Related]
19. Peptide modified gold-coated polyurethanes as thrombin scavenging surfaces.
Sun X; Sheardown H; Tengvall P; Brash JL
J Biomed Mater Res; 2000 Jan; 49(1):66-78. PubMed ID: 10559748
[TBL] [Abstract][Full Text] [Related]
20. Beyond heparinization: design of highly potent thrombin inhibitors suitable for surface coupling.
Steinmetzer T; Baum B; Biela A; Klebe G; Nowak G; Bucha E
ChemMedChem; 2012 Nov; 7(11):1965-73. PubMed ID: 22907907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
